nach oben

Erschienen in:

02.08.2018 | Study Protocol

A phase II trial to determine the cosmetic outcomes and toxicity of 27 Gy in five-fraction accelerated partial breast irradiation: the ACCEL trial

verfasst von: Petra Grendarova, Sarah Quirk, Michael Roumeliotis, Mark Lesiuk, Tammy Austin, Katelyn Bignell, Hongwei Liu, Peter Craighead, Jane Wilson, Tien Phan, Ivo A. Olivotto

Erschienen in: Journal of Radiation Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Accelerated partial breast irradiation (APBI) has been investigated in randomized controlled trials with the goals of reducing side effects and treatment burden. There is accumulating evidence that local control for multi-fraction APBI is not inferior to whole breast irradiation (WBI) but an external beam prescription that can be safely delivered in five consecutive days has not been reported. The aim of this study is to investigate an APBI prescription delivered once per day in 1 week.

Methods

This is a single-arm, phase II, prospective cohort study. Two hundred seventy-four eligible women with newly diagnosed, early-stage, invasive, or in situ ductal carcinoma treated with breast-conserving surgery and sentinel lymph node biopsy or axillary dissection who are candidates for whole breast radiation without a boost will be recruited. Twenty-seven Gray (Gy) in five fractions will be delivered once daily over five consecutive working days to the target volume. The primary outcome is the rate of global cosmetic deterioration from an excellent or good score at baseline (prior to radiation therapy) to a fair or poor score at 2 years after treatment. The study is powered to demonstrate non-inferiority compared to the use of WBI arm in the RAPID trial.

Discussion

The ACCEL trial aims to demonstrate the safe and effective delivery of a five-fraction APBI treatment using IMRT or 3D-conformal radiation. The study is designed to account for an updated α/β ratio for breast tissue and compares cosmesis to the WBI arm of the RAPID trial. The ACCEL trial was registered in February 2016 and began accrual in the subsequent May.

Conclusions

This trial will assess the cosmetic and normal tissue outcomes of external beam APBI delivered in 1 week for early-stage breast cancer.

Trial registration

Registration number: NCT02681107 (clinicaltrials.gov), registered February 2, 2016.

Fyles A, McCready D, Manchul L, Trudeau M, Merante P, Pintilie M et al (2004) Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351:963–970CrossRefPubMed

Lim M, Bellon JR, Gelman R, Silver B, Recht A, Schnitt SJ, Harris JR (2006) A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer. Int J Radiat Oncol Biol Phys 65:1149–1154CrossRefPubMed

Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31:2382–2387CrossRefPubMedPubMedCentral

Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM (2015) Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. [internet]. Elsevier Ltd 16:266–73. Available from: https://doi.org/10.1016/S1470-2045(14)71221-5 CrossRefPubMed

Canavan J, Truong PT, Smith SL, Lu L, Lesperance M, Olivotto IA (2014) Local recurrence in women with stage i breast cancer: declining rates over time in a large, population-based cohort. Int J Radiat Oncol Biol Phys [Internet]. Elsevier Inc. 88:80–6. Available from: https://doi.org/10.1016/j.ijrobp.2013.10.001 CrossRefPubMed

Njeh CF, Saunders MW, Langton CM (2010) Accelerated Partial Breast Irradiation (APBI): a review of available techniques. Radiat Oncol. [Internet] 5:90. Available from: http://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-5-90 CrossRefPubMedPubMedCentral

Olivotto IA, Whelan TJ, Parpia S, Kim D-H, Berrang T, Truong PT, et al. (2013) Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol [Internet] 31:4038–45. Available from: http://ascopubs.org/doi/10.1200/JCO.2013.50.5511

Julian TB, Costantino JP, Vicini FA, White JR, Winter KA, Arthur DW, et al (2011) Early toxicity results with 3-D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 Accelerated Partial Breast Irradiation (APBI) Trial. Int J Radiat Oncol [Internet]. Elsevier Ltd 81:S7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0360301611008352 CrossRef

Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, et al (2015) Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer [Internet]. Elsevier Ltd 51:451–63. Available from: https://doi.org/10.1016/j.ejca.2014.12.013 CrossRefPubMed

10.

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al (2002) Twenty-year follow-up of a randomized study comparing breast-Conserving surgery with radical mastectomy for early breast cancer. N Engl J Med [Internet]. 347:1227–32. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa020989 CrossRefPubMed

11.

Vicini FA, Kestin LL, Goldstein NS (2004) Defining the clinical target volume for patients with early-stage breast cancer treated with lumpectomy and accelerated partial breast irradiation: a pathologic analysis. Int J Radiat Oncol Biol Phys 60:722–730CrossRefPubMed

12.

Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM, Ciurlionis L, Chan C, Donovan EM, Emson MA, Harnett AN, Haviland JS, Hopwood P, Jefford ML, Kaggwa R, Sawyer EJ, Syndikus I, Tsang YM, Wheatley DA, Wilcox M, Yarnold JR, Bliss JM, al Sarakbi W, Barber S, Barnett G, Bliss P, Dewar J, Eaton D, Ebbs S, Ellis I, Evans P, Harris E, James H, Kirwan C, Kirk J, Mayles H, McIntyre A, Mills J, Poynter A, Provenzano E, Rawlings C, Sculpher M, Sumo G, Sydenham M, Tutt A, Twyman N, Venables K, Winship A, Winstanley J, Wishart G, Thompson A (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390:1048–1060CrossRefPubMedPubMedCentral

13.

Formenti SC, Hsu H, Fenton-Kerimian M, Roses D, Guth A, Jozsef G, Goldberg JD, DeWyngaert JK (2012) Prone accelerated partial breast irradiation after breast-conserving surgery: five-year results of 100 patients. Int J Radiat Oncol Biol Phys 84(3):606–611. https://doi.org/10.1016/j.ijrobp.2012.01039 CrossRefPubMedPubMedCentral

14.

Whelan TJ, Pignol J-P, Levine MN, Julian JA, Mackenzie R, Parpia S, et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med (Cancer Cent. Southeast. Ontario J.B.) London Reg. Cancer Cent. ;3626:513–520CrossRefPubMed

15.

Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR, START Trialists’ Group (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol [Internet]. Elsevier Ltd;14:1086–94. Available from: https://doi.org/10.1016/S1470-2045(13)70386-3 CrossRefPubMed

16.

Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, Haviland J, Bentzen S, Owen R (2005) Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 75:9–17CrossRefPubMed

17.

Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, Haviland J, Bentzen SM, Yarnold JR (2006) Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 7:467–471CrossRefPubMed

18.

Trialists TS (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9:331–341CrossRef

19.

Rose M, Olivotto I, Cady B, Koufman C, Osteen R, Silver B et al (1989) Conservative surgery and radiation therapy for early breast cancer. Long-term cosmetic results. Arch Surg 124:153–157CrossRefPubMed

20.

Beckham WA, Popescu CC, Patenaude VV, Wai ES, Olivotto IA (2007) Is Multibeam IMRT better than standard treatment for patients with left-sided breast cancer? Int J Radiat Oncol Biol Phys 69:918–924CrossRefPubMed

21.

RTOG Breast Cancer Atlas [Internet] (2017) [cited 2017 Dec 4]. Available from: https://www.rtog.org/corelab/contouringatlases/breastcanceratlas.aspx

22.

Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, Hayman JA, Jagsi R, Jolly S, Larouere J, Soriano J, Marsh R, Pierce LJ (2011) Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 79:10–18CrossRefPubMed

23.

Quirk S, Grendarova P, Roumeliotis M (2017) Five-field IMRT class solutions and dosimetric planning guidelines for implementing accelerated partial breast irradiation. Pract Radiat Oncol. Elsevier

24.

Low DA, Harms WB, Mutic S, Purdy JA (1998) A technique for the quantitative evaluation of dose distributions. Med Phys 25:656–661CrossRefPubMed

25.

Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Guinot JL, Dunst J, Miguelez CG, Slampa P, Allgäuer M, Lössl K, Polat B, Kovács G, Fischedick AR, Wendt TG, Fietkau R, Hindemith M, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, Pötter R, Gall C, Malzer M, Uter W, Polgár C (2016) 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 387:229–238CrossRefPubMed

26.

Polgár C, Fodor J, Major T, Sulyok Z, Kásler M (2013) Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiother Oncol 108:197–202CrossRefPubMed

Titel: A phase II trial to determine the cosmetic outcomes and toxicity of 27 Gy in five-fraction accelerated partial breast irradiation: the ACCEL trial
verfasst von: Petra Grendarova
Sarah Quirk
Michael Roumeliotis
Mark Lesiuk
Tammy Austin
Katelyn Bignell
Hongwei Liu
Peter Craighead
Jane Wilson
Tien Phan
Ivo A. Olivotto
Publikationsdatum: 02.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Radiation Oncology / Ausgabe 3/2018
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-018-0359-2

Neu im Fachgebiet Onkologie

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

A phase II trial to determine the cosmetic outcomes and toxicity of 27 Gy in five-fraction accelerated partial breast irradiation: the ACCEL trial